Gp Act Iii Acquisition Stock Current Valuation
| GPAT Stock | 10.42 0.02 0.19% |
Valuation analysis of GP Act III helps investors to measure GP Act's intrinsic value by examining its available valuation indicators, including the cash flow records, the balance sheet account changes and income statement patterns.
Undervalued
Today
Please note that GP Act's price fluctuation is very steady at this time. Calculation of the real value of GP Act III is based on 3 months time horizon. Increasing GP Act's time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
GP Act's intrinsic value may or may not be the same as its current market price of 10.42, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 10.42 | Real 12.23 | Hype 10.42 | Naive 10.45 |
The intrinsic value of GP Act's stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, news, and other external factors that may influence GP Act's stock price. It is important to note that the real value of any stock may change over time based on changes in the company's performance.
Estimating the potential upside or downside of GP Act III Acquisition helps investors to forecast how GPAT stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of GP Act more accurately as focusing exclusively on GP Act's fundamentals will not take into account other important factors: GP Act III Acquisition Company Current Valuation Analysis
GP Act's Enterprise Value is a firm valuation proxy that approximates the current market value of a company. It is typically used to determine the takeover or merger price of a firm. Unlike Market Cap, this measure takes into account the entire liquid asset, outstanding debt, and exotic equity instruments that the company has on its balance sheet. When a takeover occurs, the parent company will have to assume the target company's liabilities but will take possession of all cash and cash equivalents.
Current GP Act Current Valuation | 374.21 M |
Most of GP Act's fundamental indicators, such as Current Valuation, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, GP Act III Acquisition is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Enterprise Value can be a useful tool to compare companies with different capital structures. Long term liability and current cash or cash equivalents can have a huge impact on market valuation of a given company.
| Competition |
In accordance with the recently published financial statements, GP Act III Acquisition has a Current Valuation of 374.21 M. This is 98.86% lower than that of the Financial Services sector and 95.33% lower than that of the Financials industry. The current valuation for all United States stocks is 97.75% higher than that of the company.
GPAT Current Valuation Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses GP Act's direct or indirect competition against its Current Valuation to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of GP Act could also be used in its relative valuation, which is a method of valuing GP Act by comparing valuation metrics of similar companies.GP Act is currently under evaluation in current valuation category among its peers.
GPAT Fundamentals
| Return On Asset | -0.0024 | ||||
| Current Valuation | 374.21 M | ||||
| Shares Outstanding | 28.75 M | ||||
| Shares Owned By Institutions | 95.90 % | ||||
| Number Of Shares Shorted | 1.5 K | ||||
| Price To Book | 1.32 X | ||||
| EBITDA | 8.67 M | ||||
| Net Income | 8.67 M | ||||
| Total Debt | 400 K | ||||
| Book Value Per Share | (0.39) X | ||||
| Cash Flow From Operations | (584.72 K) | ||||
| Short Ratio | 0.03 X | ||||
| Earnings Per Share | 0.34 X | ||||
| Market Capitalization | 372.31 M | ||||
| Total Asset | 297.47 M | ||||
| Retained Earnings | (13.93 M) | ||||
| Working Capital | 43.75 K | ||||
| Net Asset | 297.47 M |
About GP Act Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze GP Act III Acquisition's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of GP Act using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of GP Act III Acquisition based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for GPAT Stock Analysis
When running GP Act's price analysis, check to measure GP Act's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy GP Act is operating at the current time. Most of GP Act's value examination focuses on studying past and present price action to predict the probability of GP Act's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move GP Act's price. Additionally, you may evaluate how the addition of GP Act to your portfolios can decrease your overall portfolio volatility.